Turn uncertainty into investor meetings—fast.

The founder was trying to raise $2.5 million for their CE-mark medical device, but had no connections to relevant VCs and didn’t know where to start.

We built a custom list of 140 European investors who regularly back clinical-stage healthtech. Then we wrote personalised emails using the founder’s strongest traction: a 92 % sensitivity pilot and their CE-mark timeline.

After a short strategy session, we focused outreach on funds familiar with EU medtech and clinical metrics. We crafted personalised, KPI-rich messaging that stood out in investor inboxes. Within four weeks, the campaign led to 32 positive replies and 20 confirmed investor calls. By the tenth week, three of those investors had soft-circled and moved into diligence.

The startup was raising €500,000 at pre-revenue and kept getting brushed off as “too early” or “too small.”

We reframed the story around their product-market traction: 125 % Net Revenue Retention and a 9-month CAC payback. Then we built a focused list of micro-VCs and operator-angels who invest early in SaaS.

Instead of mass emails, we targeted fewer than 6,000 investors with a sharp, two-step email sequence that highlighted real traction and lean efficiency. These investors care more about unit economics than big logos. The campaign triggered 49 positive replies and led to five meetings with serious interest. All five meetings happened within three weeks and two of them went straight into due diligence.